Using feasibility dose–volume histograms to reduce intercampus plan quality variability for head‐and‐neck cancer

Abstract

The purpose of this work is to objectively assess variability of intercampus plan quality for head‐and‐neck (HN) cancer and to test utility of a priori feasibility dose–volume histograms (FDVHs) as planning dose goals. In this study, 109 plans treated from 2017 to 2019 were selected, with 52 from the main campus and 57 from various regional centers. For each patient, the planning computed tomography images and contours were imported into a commercial program to generate FDVHs with a feasibility value ( f ‐value) ranging from 0.0 to 0.5. For 10 selected organs‐at‐risk (OARs), we used the Dice similarity coefficient (DSC) to quantify the overlaps between FDVH and clinically achieved DVH of each OAR and determined the f ‐value associated with the maximum DSC (labeled as f ‐max). Subsequently, 10 HN plans from the regional centers were replanned with planning dose goals guided by FDVHs. The clinical and feasibility‐guided auto‐planning (FgAP) plans were evaluated using our institutional criteria. Among plans from the main campus and regional centers, the median f ‐max values were statistically significantly different ( p < 0.05) for all OARs except for the left parotid ( p = 0.622), oral cavity ( p = 0.057), and mandible ( p = 0.237). For the 10 FgAP plans, the median values of f ‐max were 0.21, compared to 0.37 from the clinical plans. With comparable dose coverage to the tumor volumes, the significant differences ( p < 0.05) in the median f ‐max and corresponding dose reduction (shown in parenthesis) for the spinal cord, larynx, supraglottis, trachea, and esophagus were 0.27 (8.5 Gy), 0.3 (7.6 Gy), 0.19 (5.9 Gy), 0.19 (8.9 Gy), and 0.12 (4.0 Gy), respectively. In conclusion, the FDVH prediction is an objective quality assurance tool to evaluate the intercampus plan variability. This tool can also provide guideline in planning dose goals to further improve plan quality.